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ABSTRACT 
 Plasmodium falciparum is the blood-borne parasite responsible for the deadliest 
form of human malaria, a disease that kills up to two million people each year (1). Lack 
of effective vaccines and continued emergence of resistant strains demands the 
development of novel therapeutics for this continued global health problem (2, 3). In an 
effort to discover new drugs, we are investigating parasite expressed proteases of the 
ubiquitin-proteasome system as potential targets of therapeutic intervention. The 
ubiquitin-proteasome system regulates protein levels in all eukaryotic cells by covalent 
modification of protein substrates by ubiquitin and their subsequent direction to the 
proteasome for degradation (6). DUBs are proteases responsible for hydrolyzing the 
protein-ubiquitin bond; thus participating in multiple ubiquitin-related processes such as 
ubiquitin recycling and ubiquitin processing. Due to the increasing promise of proteases 
as drug targets for a variety of diseases and the importance of the ubiquitin-proteasome 
pathway in eukaryotes, we are interested in P. falciparum deubiquitinating proteases 
(PfDUBs) as putative drug targets (9).  
 Seventeen DUBs have recently been identified in the P. falciparum genome (11). 
Using BLASTP homology searching, we have determined that the DUBs USP14, UCH-
L5, and POH1 appear to be conserved in P. falciparum. These three DUBs are known to 
associate with the proteasome in mammalian cells and we hypothesize that in P. 
falciparum, they serve a role in ubiquitin recycling through the removal of ubiquitin from 
protein substrates prior to entering the proteasome for degradation (21, 22, 24). Since the 
presence of monomeric ubiquitin is necessary for the initial conjugation of ubiquitin to 
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substrates, disruption of ubiquitin recycling may deplete the necessary pools of 
monomeric ubiquitin.   
 To validate the essentiality of these three PfDUBs, we have used molecular 
genetic techniques to insert onto the end of their coding regions a sequence encoding a 
gene that allows us to attenuate the expression of the resulting fusion protein. Regardless 
of protein attenuation, we show that parasite death occurs in minimal media as a result of 
the C-terminal modification of either PfUSP14 or PfPOH1. Contrary to our model, 
attenuation of these PfDUBs did not appreciably deplete monomeric ubiquitin; however 
the parasites do appear to show a possible stress-related response. In addition to our 
essentiality studies, we have biochemically characterized PfUCH-L5 by tagging it with a 
hemagglutinin (HA) epitope tag. We have immunoprecipitated PfUCH-L5-HA, assayed 
for deubiquitinating activity, and assessed its biochemical properties.  
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CHAPTER 1 
 
INTRODUCTION 
 
Plasmodium falciparum is the eukaryotic pathogen responsible for the deadliest 
form of human malaria, a devastating disease that continues to be a major global health 
concern in the 21
st
 century. One-two million people die from malaria each year, making it 
the fifth leading cause of death from an infectious disease worldwide, and the World 
Health Organization (WHO) estimated up to 311 million cases in 2008 alone. About half 
of the world’s population lives in areas at risk (Fig. 1.1) (1).   
 
Figure 1.1 - Areas of the World Affected by Malaria (1). 
 
P. falciparum is a parasitic protozoan transmitted between female Anopheles 
mosquitoes and humans. The parasite has a complex cycle in which meiosis occurs in the 
mosquito, with haploid forms in the humans hosts (Fig. 1.2). Briefly, during a blood 
meal, sporozoites from a malaria-infected mosquito migrate to and infect liver 
hepatocytes. The parasite replicates within the hepatocyte, eventually releasing hundreds 
of daughter merozoites into the circulatory system, which invade and infect erythrocytes, 
beginning what is termed the erythrocytic cycle. This portion of the life-cycle is 
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responsible for disease pathology through the continuous cycle of invasion and 
destruction of erythrocytes approximately every 48 hours. Up to 32 merozoites can 
emerge from a single infected erythrocyte. Concurrently, some of these erythrocyte stage 
parasites differentiate into sexual gametocytes which the mosquito takes up during a 
blood meal, thus transmitting the parasite back to the mosquito.  
 
Figure 1.2  – Life cycle of Plasmodium falciparum (1). The sporogonic cycle consists of stages in the 
mosquito. The exo-erythrocytic cycle consists of the liver stages; the initial site of infection. The 
erythrocytic cycle is responsible for the disease causing stages of P. falciparum. Sexual gametocytes can 
differentiate from the erythrocytic stages and be transmitted back to mosquitoes in the sporogonic cycle.  
 
 Symptoms of the disease are similar to influenza and include fevers, chills, 
headaches, and body aches. A hallmark identifier is the recurring fever every 48 hours 
due to the synchronous rupture of the parasites during the erythrocytic cycle resulting in a 
massive cytokine response. Severe cases of malaria cause patients to suffer from anemia 
from erythrocyte hemolysis, blood coagulation, and cerebral-malaria, the most common 
cause of death
 
(1).  
Despite the availability of therapeutics, malaria continues to be a modern global 
health problem due to a wide range of factors. To date, no effective vaccine has been 
developed for malaria. Without even a promising vaccine in the pipeline, the 
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development of an effective vaccine is likely many years from fruition (2). A more 
pressing obstacle to the malaria problem is drug resistance. As of 2011, every known 
antimalarial has encountered some form of resistance
 
including the mainstay artemisinin-
based combination therapies (3), the most preferable and potent antimalarial
 
(4). Due to 
these factors, the development of novel therapeutics and new target discovery is 
desperately needed.  
 In our efforts to discover new drug targets, we are considering proteases that have 
a role in the ubiquitin-proteasome system. Proteases have been considered promising 
drug targets (5) and the ubiquitin-proteasome system serves as a key pathway in protein 
homeostasis in eukaryotes. The 26S proteasome is a multisubunit proteolytic complex 
conserved in eukaryotic cells whose role is to degrade protein substrates modified by 
ubiquitin (Fig. 1.3) (6). Ubiquitin is a small, highly conserved protein in eukaryotes 
responsible for a variety of cellular functions. In the ubiquitin-proteasome pathway, 
ubiquitin modifies a target protein through a covalent isopeptide bond in specific lysine 
residues in the protein substrates. This modification is catalyzed through three successive 
enzymatic steps mediated by an E1 activating enzyme, an E2 conjugating enzyme, and an 
E3 ligase. Ubiquitin itself also contains specific lysine residues used for conjugation of 
multiple ubiquitin monomers to generate polyubiquitin chains.  Polyubiquitinated chains 
on a lysine-48 residue of a target protein are a common degradation signal recognized by 
the proteasome (7, 8) (Fig. 1.3a).  
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Figure 1.3 – Deubiquitinating proteases and the ubiquitin-proteasome system. (A) Covalent conjugation of 
ubiquitin to protein substrates is mediated by E1, E2, and E3 enzymes. Successive ubiquitination of 
substrates yields polyubiquitinated products. The proteasome hydrolyztes ubiquitinated substrates into 
individual amino acids. (B) Various functions and processes of deubiquitinating proteases and other 
paralogs.  
 
Deubiquitinating proteases (DUBs) are proteases responsible for hydrolyzing the 
covalent protein-ubiquitin bond, reversing the actions mediated by the E1, E2, and E3 
enzymes. They are thought to be involved in a variety of processes such as ubiquitin 
processing, ubiquitin recycling and as an antagonist to ubiquitin ligases (Fig. 1.3b)
 
(9). 
A 
B 
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Approximately 100 putative DUBs appear to be encoded in the human genome (10), and 
about seventeen putative DUBs have been identified in the P. falciparum genome (11). 
Most of these PfDUBs remain uncharacterized and as yet, none have been validated as 
possible drug targets.  
Here we use genetic approaches to manipulate and modify the P. falciparum 
genome in an effort to validate PfDUBs as drug targets by assessing their essentiality 
during the parasite’s erythrocytic cycle. P. falciparum lacks RNAi capability (12); 
therefore the main difficulty to our goal is to specifically attenuate the protein level of 
each PfDUB. We have taken advantage of a recently developed gene-tagging approach 
which allows for tunable protein levels (13). Although such approaches are state of the 
art, obtaining clonal transgenic lines is difficult, requiring approximately 3 months time. 
In addition, we have used a similar gene-tagging strategy to purify and biochemically 
characterize the deubiquitinating activity for one PfDUB using an in vitro fluorogenic 
assay.  
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CHAPTER 2 
PLASMDOIUM FALCIPARUM PROTEASOMAL DUBS 
 Ponder et al. identified seventeen putative DUBs in the P. falciparum genome 
(11). Using the identified genes, we obtained their amino acid sequences from the fully 
sequenced P. falciparum genome (14, 15) and performed a BLASTP homology search on 
each DUB’s closest human homologs (Appendix A and C). We observed that the three 
proteasomal DUBs, USP14, UCH-L5, and POH1 appear to be conserved in P. 
falciparum. In mammalian systems, these DUBs associate with the 19S regulatory cap of 
the proteasome (Fig 2.1) to remove polyubiquitin chains from substrates prior to entering 
the proteasome’s proteolytic site. Thus, these DUBs are likely responsible for ubiquitin 
removal and recycling. Due to the reported essentiality of the proteasome in P. 
falciparum (16), we are interested in the essentiality of these three associated DUBs 
during the parasite’s erythrocytic stages.  
 
Figure 2.1 – Association of USP14, UCH-L5, and POH1 with the 19S regulatory cap (pink) of the 
proteasome. The alpha and beta subunits of the proteasome are labeled blue and orange respectively. 
Adapted from Wilkinson, et al (11).  
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 USP14 is a cysteine protease which becomes activated upon binding to the 
proteasome cap (17). Deletions of USP14 in mice cause ataxia and defects associated 
with depletions in monomeric ubiquitin (18). Likewise, UCH-L5 (also a cysteine 
protease) has similar roles to USP14 in the proteasome and likely works in tandem with 
USP14 to trim multiple polyubiquitinated chains (19). Although UCH-L5 may have a 
redundant proteasomal deubiquitinating role to USP14, P. falciparum UCH-L5 also 
appears to have Nedd8 hydrolase activity, an activity not conserved in the human 
homolog of UCH-L5 (20). Nedd8 is a ubiquitin-like protein that post-translationally 
modifies the cullin family of proteins (11).  
 POH1 is a zinc-dependent metalloprotease which also localizes to the proteasome 
cap. POH1 can remove entire polyubiquitin chains from protein substrates, a function not 
observed for USP14 and UCH-L5 (21). POH1 has been demonstrated to be essential in 
yeast and humans (22) and it is thought to be a subunit of the proteasome (21).  
In our genetic approach to assess the essentiality of these three putative 
proteasomal PfDUBs, we have used a protein attenuation system to attenuate the protein 
levels of each PfDUB (13). Using this system, we have generated transgenic lines of P. 
falciparum parasites in which the 3’ end of the gene of interest is tagged with a gene 
coding for a destabilizing domain (dd). This destabilizing domain is a mutated 
dihydrofolate-reductase protein (DHFRdd), whose stability is dependent on the small 
molecule ligand trimethoprim (TMP). Removal of TMP results in misfolding and 
degradation of the DHFRdd (Fig. 2.2). By tagging the 3’ end of the DUB gene with the 
coding region for DHFRdd, we are able to generate a gene which will code for a DUB-
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DHFRdd fusion protein. Consequently, the abundance of a DUB-DHFRdd fusion protein 
can be attenuated post-translationally by removal of TMP.  
 
 
 
Figure 2.2 – Integration strategy of pGDBvm into the P. falciparum genome. The 3’ end of the GOI is 
cloned in-frame with the GFP-DHFRdd-HA domain to generate the PfDUB-DHFRdd fusion protein whose 
stability is dependent on TMP.   
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To tag a DUB of interest with DHFRdd, we cloned a targeting fragment 
containing the 3’ end of the gene of interest (GOI) into the pGDBvm plasmid 
(Muralidharan, Fig. 2.2). After successful cloning of each targeting fragment into 
pGDBvm, the resulting plasmids are then electroporated into P. falciparum parasites to 
undergo single crossover homologous recombination, thus tagging the native locus of the 
DUB (Fig. 2.2). For these experiments, all transfections were carried out in the parental 
line ΔPM1-3D7, a clonal, transgenic line which provides a stably integrated and 
expressed human DHFR gene which is resistant to TMP. We obtained clonal lines of 
integrant parasites using a strategy of on/off drug pressure followed by limiting dilution.  
 Proteasomal DUBs PfUSP14, PfUCH-L5, and PfPOH1 are expressed in P. 
falciparum’s erythrocytic stages. Microarray data found on the PlasmoDB website 
suggested maximal expression for these PfDUBs during the parasite’s most metabolically 
active trophozoite-stages (15). We therefore confirmed correct integration of our clonal 
lines by western blotting cell lysate of trophozoite-stage parasites. Total parasite lysate 
was separated by denaturing SDS-PAGE, and the fusion protein was detected using anti-
HA anti-sera (Fig. 2.3 a). In addition to DHFRdd, we also successfully tagged the 3’ end 
of PfUSP14 and PfUCH-L5 in a similar strategy with just the coding region for HA, a 1 
kDa epitope tag. The observed molecular weight of each PfDUB appears to be consistent 
with the predicted molecular weight, suggesting these DUBs are not post-translationally 
modified. Additionally, primers  designed to analyze integration into PfUSP14’s locus 
confirmed integration of the plasmid by PCR, providingfurther evidence for correct 
integration (Fig. 2.3 b).  
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Figure 2.3 – Successful tagging of PfUSP14, PfUCH-L5, and PfPOH1 with either DHFRdd or HA. (A) 
Anti- HA western blot of trophozoite-stage parasites for PfUCH-L5-HA (Clone F6) and PfUSP14-HA 
(Clone D10) and the DHFRdd constructs: PfUCH-L5-DHFRdd Clone A12, PfUSP14-DHFRdd Clone A5, 
and PfPOH. Concentration of TMP is noted and reflects 48 hour treatment/removal. (B) Genotyping of 
PfUSP14 by PCR confirms integration into the correct locus. (C) Anti-HA western blot of trophozoite-
stage parasites for PfAtaxin-3-DHFRdd (Clone H9) and PfATG7-DHFRdd (Clone A1). TMP concentration 
is noted and reflects 48 hour treatment/removal.  
 
 Attenuation of the Proteasomal DUB expression by removal of TMP. TMP 
removal should result in misfolding of the DUB-DHFRdd fusion followed by degradation 
by the proteasome. Attenuation of each PfDUB-DHFRdd appears to be effective after 48 
hours post TMP washout, but attenuation is relatively inefficient (Fig.2.3 a). In unrelated 
A 
C 
B 
Anti-HA 
Anti-HA 
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experiments, our lab has used this system to attenuate cellular levels of PfAtaxin-3-
DHFRdd and PfATG7-DHFRdd with much greater efficiency (Fig. 2.3 c). PfAtaxin-3 
and PfATG7 are independent of the ubiquitin-proteasome pathway and one possible 
explanation for the inefficiency in attenuating our proteasomal DUBs is that their 
inhibition impairs the degradation efficiency of the proteasome, which is necessary for 
this attenuation system. It was previously demonstrated that complete inhibition of the 
proteasome by lactacystin blocks replication of parasites (16). Therefore, attenuation of 
these PfDUBs may impair proteasome function, without the ability to inhibit it 
completely.  
 Modification of the proteasomal DUBs appears to affect parasite growth. In 
culturing conditions using the standard rich media RPMI 1640, we have not observed any 
morphological or growth phenotype of our transgenic lines. However, growth of these 
lines is slower than the parental ΔPM1-3D7 strain in the minimal isoleucine-only growth 
media (I-Media) regardless of the presence of TMP (Fig. 2.4 a-c). Although RPMI 1640 
is a media that is ideal for sustained parasite growth, we used I-media to force the 
parasite to rely solely on its protein catabolic processes to generate amino acids 
(isoleucine is the only amino acid the parasite cannot obtain from catabolism of host cell 
hemoglobin (23)). The lack of TMP dependence is possibly due to the presence of the 
bulky C-terminal DHFRdd tag (~47 kDa), which might inhibit the protein’s localization 
or enzymatic properties. Due to the inefficiency of degradation of PfUCH-L5 and 
PfUSP14 upon removal of TMP (Fig. 2.3a), this C-terminal tag may also disrupt normal 
proteasome function, which could explain the observed growth phenotype.  
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Figure 2.4 – Analysis of PfUSP14, PfUCH-L5, and PfPOH1 protein attenuation when grown in I-media. 
(A-C) Asynchronous cultures of PfUSP14-DHFRdd clone A5, PfUCH-L5-DHFRdd clone A12 (noted as 
UCH), and PfPOH1 mixed cultures were grown in the presence and absence of 0.5 μM TMP. Growth was 
compared with the parental ΔPM1-3D7 with similar conditions. (D-F) Analysis of synchronous PfDUB-
DHFRdd cultures in the presence and absence of 0.5 μM TMP . Parasite growth was monitored by flow 
cytometry and cultures were grown in I-media (see Materials and Methods).  
 
Besides a slow growth phenotype, PfUSP14-DHFRdd and PfPOH1-DHFRdd 
populations grown in I-media eventually die (Fig. 2.4 d and f). This suggests these DUBs 
to be essential under nutrient limiting conditions. In contrast, growth of PfUCH-L5 
appears to stall then eventually recovers. distinguishing this PfDUB from PfUSP14 and 
PfPOH1, indicating it may not be essential.  
It was previously observed in other systems that ubiquitin monomer depletion is 
deleterious for cells (24). We hypothesized that attenuation of these putative proteasomal 
DUBs could result in an impaired ability to recycle ubiquitin. To explore this idea, we 
C 
D 
F 
E B 
A 
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assessed ubiquitin monomer levels by western blotting at various concentrations of TMP 
(Fig. 2.5). Contrary to our hypothesis, ubiquitin monomers did not appear to be depleted 
in the absence of TMP in the PfUSP14-DHFRdd and PfUCH-L5-DHFRdd lines. In fact, 
attenuation of PfUSP14 and PfUCH-L5 levels had an opposite effect, as monomeric 
ubiquitin depletion appeared to increase (Fig. 2.5). Also observed was an increase in 
ubiquitinated proteins. This increase in ubiquitinated proteins is similar to the effects of 
the proteasome inhibitor MLN-273, which further suggests attenuation of PfUSP14 or 
PfUCH-L5 results in impaired proteasome function (25). One possible explanation for 
this is that the parasite can respond to reduced ubiquitin monomer pools by upregulating 
ubiquitin expression. A proposed experiment to determine if ubiquitin is upregulated is 
described in Appendix D.  
The slow-growth phenotype in these experiments might be due to an indirect 
effect of impairment of the proteasome through a starvation related stress response. One 
observation that supports this idea came from our attempt to use the structural protein 
actin as a loading control for our attenuation experiments (Fig. 2.3 a). Surprisingly, actin 
levels rose as TMP concentration was reduced for both the PfUSP14-DHFRdd or 
PfUCH-L5-DHFRdd cell lines. An increase in ubiquitinated proteins has also been 
demonstrated to be a stress response (26). Therefore, it is possible the growth phenotypes 
observed for PfUSP14 may be due to an impaired proteasome function that causes stress. 
An experiment to directly assay proteasome efficiency is proposed in Appendix D.  
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Figure 2.5 - Attenuation of proteasomal DUBs may induce stress-related response.  Western blot of 
PfUSP14-DHFRdd clone A5 and UCH-L5-DHFR clone A12 with human ubiquitin anti-sera at varying 
TMP concentrations (upper panel). Membrane was stripped and was then re-probed with actin-antisera 
(lower panel).   
  
A more direct possibility for the slow growth phenotype in PfUSP14-DHFRdd 
and PfPOH1-DHFRdd may be due to a limited supply of amino acids. Parasites in I-
media are forced to rely on the protein catabolic processes of the lysosome and the 
proteasome. In RPMI 1640, the parasite has access to an abundant supply of exogenous 
amino acids from the media. If the growth phenotype is indeed attributable to amino acid 
starvation, could adding back cysteine, glutamine, glutamate, and methionine rescue the 
parasites grown in I-media? These amino acids are present minimally in hemoglobin, a 
major catabolic source of amino acids for the parasite (23). This experiment is currently 
Anti-actin 
Anti-ubiquitin 
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in progress. Additionally, phosphorylation of eIF2α, which is known to occur during 
amino acid starvation will be assessed by western blotting (see Appendix D) (27). 
Biochemical characterization of PfUCH-L5. Using an integration strategy similar 
to the pGDBvm plasmid, we have tagged the 3’ end of the PfUSP14 and PfUCH-L5 
genes with the coding region the HA epitope to allow for purification of native protein 
for biochemical assays. We successfully obtained integrants in PfUSP14-HA clone A11 
and PfUCH-L5 clone F6. (Fig. 2.3 a, HA tag lines). Using HA anti-sera, we 
immunoprecipitated each PfDUB-HA fusion protein and carried out in vitro assays for 
deubiquitinating activity using the fluorogenic ubiquitin substrate Ubiquitin-AMC. 
PfUCH-L5, like its human homolog, can hydrolyze Ub-AMC and its activity can be 
inhibited by the inhibitor ubiquitin-aldehyde (Fig. 2.7 a) (28). As shown, we did not 
observe PfUSP14 activity, which is consistent with human USP14 activity assays with 
Ub-AMC (29). This could suggest that Ub-AMC is not the ideal substrate for USP14 
since western blotting detects presence of purified PfUSP14. We were however able to 
detect activity for PfUCH-L5-HA, measuring a Michaelis constant (Km) of 699.0 nM 
(Fig. 2.7 b). The measured Km is similar to those for PfUCH-L3 and HsUCH-L3, 
identified by Artavanis-Tsakonas et al of 301 nM and 162 nM respectively (30). Kcat 
was not calculated due to the unknown quantity of PfUCH-L5 present in the reaction.  
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Figure 2.6 -  Biochemical Characterization of PfUSP14 and PfUCH-L5. (A) Ubiquitin-AMC is a 
fluorogenic substrate that emits a fluorescent signal after cleavage by a deubiquitinating enzyme. 
Ubiquitin-aldehyde is an irreversible inhibitor of the reaction. (B) Relative florescence over time of 
immunoprecipitated PfUSP14-HA clone A11 and PfUCH-L5 clone F6 (noted as UCH) in the presence and 
absence of ubiquitin-aldehyde. (C) Anti-HA western blot of PfUSP14 lysate, supernatant, and 
immunoprecipitate showing presence of PfUSP14 despite no activity from (B). (D) Kinetic analysis of 
PfUCH-L5 determines a Km. of 699 nM.  
 
 
 
A 
B 
C 
D 
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CHAPTER 3 
DISCUSSION 
 We have carried out the initial characterization of the P. falciparum DUBs 
PfUSP14, PfUCH-L5, and PfPOH1. Our studies suggest them to be associated with the 
proteasome, indicating their roles to be conserved in P. falciparum erythrocytic-stage 
parasites. Although the functions appear to be conserved, sequence alignments to their 
respective human homologs show differences in the primary amino acid sequence 
(Appendix C). Although these studies suggest the potential druggability of these 
proteases in P. falciparum, further modeling and structural studies are needed to address 
the feasibility of the design of selective inhibitors. 
 Due to the lack of RNAi in P. falciparum, our approach in evaluating the 
essentiality of these DUBs consisted of manipulating the parasite genome to tag the 3’ 
end of each PfDUB gene with a sequence encoding a destabilization domain (DHFRdd). 
By removing the stabilizing ligand TMP, we attenuated the expression of each DUB post-
translationally. Although we have evidence suggesting the essentiality of PfUSP14 and 
PfPOH1, a rigorous attempt to delete these genes by knockout approaches needs to be 
carried out. Failure to achieve a knockout in these haploid parasites would serve as the 
strongest evidence for essentiality.  
 These studies have provided us evidence of essentiality during parasite growth in 
minimal media. In minimal media, P. falciparum’s only sources of amino acids are from 
protein catabolic processes such as the ubiquitin-proteasome system and the lysosome. 
Regardless of TMP concentration, tagging of PfUSP14 and PfPOH1 with a bulky C-
terminal domain may impair normal function of the PfDUB and/or the proteasome. These 
25 
 
transgenic parasites, when grown in I-media, die in as little as 3-4 days. This may be 
attributed to stress related to amino acid starvation. We will address this possibility by 
adding back the four additional amino acids found in limited amounts in hemoglobin, 
which could rescue the parasite from amino acid starvation.  
 Knockout of PfUSP14 and PfUCH-L5 in yeast and mice have suggested toxicity 
to cells resulting from ubiquitin monomer depletion. Due to their association with the 
proteasome, these DUBs are suggested to function in ubiquitin recycling by cleaving 
ubiquitin from protein substrates prior to proteasomal degradation. Thus, attenuating each 
PfDUB could result in a decrease of monomeric ubiquitin. However, we observed an 
apparent increase in monomeric ubiquitin. Additionally, there was an increase in 
ubiquitinated proteins in PfUSP14 and PfUCH-L5 attenuated parasites which would be 
consistent with impaired proteasome function. Another possibility is this increase is 
associated with a parasite stress response. Further studies can investigate this idea by 
examining if this increase in monomeric ubiquitin is due to a stress-induced upregulation 
of ubiquitin transcription.  
 Normal proteasome function may be impaired in the absence of TMP, but we 
have not quantitatively determined this. Western blotting of PfATG7-DHFRdd and 
PfAtaxin-3-DHFR dd attenuated lines (not subjects of this study) suggests degradation of 
these cytosolic proteins was significant after 48 hours, yet in PfUSP14 and PfUCH-L5, 
attenuation efficiency was less robust. This may suggest an inherent difficulty in utilizing 
a strategy involving proteasomal mediated degradation to examine proteins essential to 
proteasome function. Assays to directly measure degradation efficiency in the attenuated 
lines should confirm if the proteasome is truly impaired.  
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 The growth phenotypes of PfUSP14 and PfPOH1 do, however, suggest they are 
essential to the parasite and that these proteases may be targets for novel antimalarial 
therapeutics.  In our initial assays, PfUCH-L5 appears to be non-essential due to its 
functional redundancy to PfUSP14. This study provides, to our knowledge, the first 
insights into the role of the proteasomal DUBs in P. falciparum, a medically relevant 
parasitic protozoa highly reliant on protein catabolic processes. Although such pathways 
are conserved in human cells, these proteases have shown considerable promise as targets 
for anti-cancer therapeutics due to the cancerous cell’s susceptibility to alterations in 
protein homeostasis (31). For this reason, a number of proteasomal inhibitors have been 
explored as anti-cancer therapeutics (bortezomib). We feel a similar situation might be 
true for P. falciparum and further studies will be carried out to assess the potential 
selectivity of PfDUB inhibitors possibly serving to validate these enzymes as bona fide 
drug targets for P. falciparum.  
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CHAPTER 4 
MATERIALS AND METHODS 
Materials 
The pGDBvm plasmid was kindly obtained from Dr. Vasant Muralidharan, 
Washington University in St. Louis. The pM2GT-HA plasmid was obtained from Dr. 
Michael Klemba, Virginia Polytechnic Institute and State University.  
Plasmid Construction 
3D7 strain parasite genomic DNA was purified from P. falciparum parasites using 
the Blood Mini Kit (Qiagen). Primers were designed to amplify a ~1 kb fragment of the 
3’ end of each PfDUB and contained restriction sites for Xho I and AvrII (Appendix B). 
The PfDUB 3’ fragment was amplified by PCR using Taq Hi fidelity DNA polymerase 
(Invitrogen) and cloned into the TOPO TA sequencing vector (Invitrogen). Each insert 
was confirmed by sequencing and fragments were digested with XhoI and AvrII and 
ligated into pM2GT-HA (Klemba) and pGDBvm (Muralidharan). Plasmids were 
maintained in E. coli DH5α (Invitrogen).  
Parasite Culture and Transfection 
 P. falciparum (3D7 and ΔPM1-3D7 strain) parasites were cultured in human O+ 
erythrocytes as previously described (32) and grown at 2% hematocrit in RPMI 1640 
medium enriched with gentamycin and albumax. Parasites were grown at 37°C under 5% 
O2, 5% CO2, and 90% N2. Parasite cultures were synchronized using 5% D-sorbitol (33).  
 Ring stage parasites (3D7 for pM2GT-HA constructs and PM1-3D7 for pGDBvm 
constructs) were transfected with 100 μg of plasmid DNA using electroporation (34) and 
clonal integrants were obtained by cycling of drug pressure as previously described (35). 
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The PfPOH-DHFRdd lines used in this study were non clonal and finished 2
nd
 cycle of 
drug pressure.  
Parasite Purification from Human Erythrocytes 
 Parasites were purified from host red blood cells by incubation in a .025% 
saponin/phosphate-buffered saline (PBS) solution for 5 minutes followed by cold PBS 
washes supplemented with Complete Protease inhibitor (Roche).  
Western blotting 
 Parasite lysate was resuspended in 1X SDS sample loading buffer, boiled for 5 
min., and separated by SDS-PAGE. Loading of each lane was by equal parasite number 
of approximately 1x10
7
 parasites per lane. Electrophoretic transfer occurred onto a 
nitrocellulose membrane (GE Healthcare) 100 volts for 30 minutes. Membrane was 
washed and blocked using a 5% non-fat dry milk/tris-buffered saline-tween20. Rabbit 
anti-HA antisera (Abcam) was diluted 1:5,000 and detected by chemiluminescence using 
horse radish peroxidase-conjugated donkey anti-rabbit secondary (GE Healthcare) 
1:10,000. Signal was visualized by exposure to X-ray film after application of an ECL kit 
(Supersignal West Dura, Thermo Scientific). Anti-ubiquitin western blotting used rabbit 
anti-human ubiquitin sera (Abcam). Anti-actin western blotting used goat anti-human 
actin sera (Santa Cruz) 1:2,000 and detected with a donkey anti-goat antisera (Santa 
Cruz) 1:5,000. Stripping of membranes was by 2% SDS-62 mM Tris (6.7pH)- 7.8uL/mL-
TBS-T solution.   
Parasite Growth Analysis 
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 Parasitemia was using a high throughput sampler on a BD FacsCanto II flow 
cytometer. 5 μL parasite populations were resuspended in 100 μL of a 1.5 μg/mL-
acridine orange-PBS solution. Parasitemias were graphed onto Microsoft Excel.  
Immunoprecipitation 
8x10
8 
parasites of trophozoite-stage parasites were purified as described. Lysate was 
resuspended in PBS, sonicated, followed by addition of triton X-100 (1%). Anti-HA 
antisera and Protein G/Protein A conjugated agarose beads were added and incubated for 
1 hour. Supernatant was removed and saved for western blotting. Immunoprecipitate  was 
washed 5 times with PBS and final solution was suspended in PBS.  
Ubiquitin-AMC Activity Assay and kinetic analysis 
 Immunoprecipitated PfDUB-HA proteins were incubated with 0.5 μM Ubiquitin-
AMC (Enzo) and relative fluorescence was measured on a Spectra Max Plate Reader 
using excitation and emission wavelengths of 380 and 460 nM respectively (Molecular 
Devices). For inhibition, 0.1 μM ubiquitin-aldehyde (Enzo) was preincubated with 
immunoprecipitate prior to addition of substrate in the same conditions. Assay buffer 
consisted of 50 mM HEPES, 0.5 mM EDTA, 1 mM DTT, and 0.1 mg/mL BSA.  
 For kinetic analyses, PfDUB-HA was incubated at concentrations of 1 μM, 0.5 
μM, 0.25 μM, 0.125 μM, and 0.0625 μM of ubiquitin-AMC. Data was imported into the 
PRISM software (GraphPad Software) and a Km was calculated.  
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APPENDIX A 
TABLE OF IDENTIFIED DUBS IN P. FALCIPARUM 
PFALCIPARUM 
GENE  
CLOSEST 
HUMAN 
HOMOLOG  
SUB-FAMILY  DUB FUNCTION 
IN HUMANS  
ESSENTIAL?  
PF14_0576  UCH-L3  Ubiquitin C-
Terminal Hydrolase  
Process multimeric 
ubiquitin  
Yes  
PF11_0177  UCH-L5  Ubiquitin C-
Terminal Hydrolase  
Deubiquitinating and 
deneddylating 
activity; associates 
with proteasome  
Unknown  
MAL7P1.147  USP7/HAUSP  Ubiquitin Specific  
Protease  
P53 and Mdm2 
deubiquitination.  
Unknown  
PFA0220w  USP36  Ubiquitin Specific  
Protease  
Unknown  Unknown  
PFD0680c  USP5/Isopeptidase 
T  
Ubiquitin Specific  
Protease  
Process ubiquitin 
chains to recycle 
ubiquitin  
Unknown  
PFE1355c  USP14  Ubiquitin Specific  
Protease  
Disassembles 
polyubiquitin chains 
at proteasome; 
ubiquitin recycling  
Unknown  
PFE0835w  USP4  Ubiquitin Specific  
Protease  
Rho52 
deubiquitination.  
Unknown  
PFI0225w  USP42  Ubiquitin Specific  
Protease  
Unknown  Unknown  
PF13_0096  USP39  Ubiquitin Specific  
Protease  
Unknown  Unknown  
PF14_0145  UCH36  Ubiquitin Specific  
Protease  
Unknown  Unknown  
PFL1295w  Ataxin-3  Josephin Domain  Deubiquitinates K63-
ubiquitinated 
proteins  
Unknown  
MAL13P1.343  POH1/Proteasome 
Subunit 14  
Jab1/MPN/Mov34 
Metalloenzyme  
Catalyzes release of 
polyubiquitin chains 
at proteasome; 
subunit of 
proteasome  
Unknown  
PFL0865w  PPPDE   Unknown  Unknown  
PFL1635w  Sumo/sentrin 
Specific Peptidase 
1  
Desumoylase  Desumoylating 
activity  
Unknown  
MAL8P1.157  Ulp2 (S. pombe)  Desumoylase  Desumoylating 
activity  
Unknown  
PF10_0092  Wss1p (S. 
cerevisiae)  
Metalloprotease  Unknown 
metalloprotease  
Unknown  
PF14_0171  ATG4  ATG8 C-Terminal 
Hydrolase  
Autophagy pathway  Unknown  
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APPENDIX B 
PRIMERS USED TO CLONE EACH PFDUB GENE 
PfUSP14 For : CTCGAGGGAAACTGTTGAACAACATG 
Rev: CCTAGGTTCCTTAATATCCATATTCAT 
PfUCH-L5 For: CTCGAGTGCATGTGCTACACAAGCTA 
Rev: CCTAGGCGAAATCATAAATGTTTCCT 
PfPOH1 For: CCTTCTCGAGAGTACCTATGGAAGTT 
Rev: CCTCCCTAGGAAAGAACAGAGTATTTG 
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APPENDIX C 
PFDUB SEQUENCE ALIGNMENTS WITH HUMAN HOMOLOGS 
USP14 
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UCH-L5 
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POH1 
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APPENDIX D 
UNANSWERED QUESTIONS AND PROPOSED EXPERIMENTS 
Is ubiquitin upregulated in response to disruption of ubiquitin recycling? 
Our results from the anti-ubiquitin western blot (Fig. 2.5) suggest that there was not a 
depletion of ubiquitin monomers in our PfUSP14-DHFRdd and PfUCH-L5-DHFRdd 
attenuated lines, contrary to our hypothesis. However, this does not reject our hypothesis, 
as ubiquitin could be upregulated in response to stress. In order to determine if ubiquitin 
is upregulated transcriptionally, quantitative PCR or northern blotting can confirm if the 
RNA levels of ubiquitin is increased in the stressed PfDUB attenuated lines.  
Are the growth phenotypes observed due to impaired proteasome function? 
We have some evidence of impaired proteasome function due to the incomplete 
degradation of PfUSP14 and PfUCH-L5 and an accumulation of ubiquitinated-proteins. 
However, we do not have quantitative or kinetic data to confirm impaired function. One 
approach includes purification of P. falciparum proteasomes by immunoprecipitation and 
comparing activity in the PfDUB attenuated lines and wild type lines. This assay is 
dependent on the identification of a substrate whose degradation can be monitored by 
fluorescence for example.  
Alternatively, we can also assay if sensitivity to known proteasome inhibitors is 
affected. Using a known inhibitor such as epoxomicin or bortezomib, we can determine if 
the IC50 values of these inhibitors are decreased from wild type strains, suggesting an 
increase in proteasome sensitivity.  
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Is the phenotype with PfUSP14 associated with a bulky C-terminal adduct? 
PfUSP14-DHFRdd lines stalled and eventually died in I-media regardless of the 
presence of TMP. To assess if PfUSP14’s normal function is inhibited by the C-terminal 
adduct, an activity assay will be performed. However, this assay depends on the 
identification of a substrate for PfUSP14 since we have determined that it cannot cleave 
Ub-AMC.  
 Likewise, the bulky C-terminal adduct may be inhibiting localization into the 
proteasome, which could answer why PfUSP14-DHFRdd lines grew slower regardless of 
the TMP concentration. To test this, we can use fluorescence microscopy to determine if 
they co-localize. A non-essential proteasome subunit can be tagged with a different 
fluorescent reporter such as RFP and expressed episomally. We can now determine co-
localization since there is a GFP domain in the pGDBvm plasmid.  
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